PF 3814735

Drug Profile

PF 3814735

Alternative Names: PF-03814735; PF-3814735

Latest Information Update: 29 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Acetamides; Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 27 Sep 2010 Discontinued - Phase-I for Solid tumours in Belgium (PO)
  • 27 Sep 2010 Discontinued - Phase-I for Solid tumours in USA (PO)
  • 03 Jun 2008 Interim pharmacokinetics and adverse events data from a Phase-I trial in Solid tumours presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top